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Introduction: Recent clinical trials revealed that accurate histologic
typing of non-small cell lung cancer, especially squamous cell
carcinoma (SCC), is essential.
Patients and Methods: We analyzed 10 antibodies expression in
150 SCC cases (53 well-, 51 moderately, and 46 poorly differenti-
ated cases) and 159 adenocarcinoma (AC) cases (49 well-, 52
moderately, and 58 poorly differentiated cases).
Results: In all SCC and AC cases, p63 was the most sensitive
marker for SCC (98.7%), followed by high-molecular-weight (HM)
cytokeratin (CK) (97.3%), CK5/6 (93.3%), Sox2 (80%), thrombo-
modulin (79.3%), desmocollin-3 (72.7%), S100A7 (70.7%),
S100A2 (63.3%), and glypican-3 (46.7%). Desmocollin-3 was the
most specific marker for SCC (100%), followed by CK5/6 (98%),
Sox2 (95.5%), glypican-3 (92.4%), S100A7 (86.8%), thrombo-
modulin (79.9%), S100A2 (64.6%), p63 (51.6%), and HMCK
(33.3%). Thyroid transcription factor-1 (TTF-1) expression was
observed in 87.4% of AC cases and 2.0% of SCC cases. When
analyzing only poorly differentiated tumors, HMCK was the most
sensitive marker for SCC (100%), followed by p63 (97.8%), CK5/6
(87.0%), Sox2 (71.7%), thrombomodulin (58.7%), desmocollin-3
(52.2%), S100A2 (50%), glypican-3 (45.7%), and S100A7 (45.7%).
Desmocollin-3 was the most specific marker for poorly differenti-
ated SCC (100%), followed by CK5/6 (98.3%), glypican-3 (94.8%),
Sox2 (94.8%), S100A2 (81%), S100A7 (75.9%), thrombomodulin
(72.4%), p63 (48.3%), and HMCK (36.8%). The 10-fold crossvali-
dated classification and regression tree analysis revealed that the
combination of CK5/6 and TTF-1 was the best immunohistochem-
ical marker panel for the differentiation between SCC and AC.
Conclusion: CK5/6 is the best marker for differentiating SCC and
AC, irrespective of the histological grade of the tumor. Thus, the
combination of CK5/6 and TTF-1 is the most recommended com-
bination of immunohistochemical markers.
Key Words: Squamous cell carcinoma, Lung, Cytokeratin 5/6,
Sox2, Desmocollin-3.
(J Thorac Oncol. 2011;6: 1190–1199)
Although the lung cancer is subdivided into four majorhistologic types, including small cell carcinoma
(SCLC), and squamous cell carcinoma (SCC), adenocar-
cinoma (AC), and large cell carcinomas (LCC), in the
latest edition of the World Health Organization classifica-
tion1 until recently, histologic typing of non-small cell
lung carcinoma (NSCLC) was not clinically or therapeu-
tically important. Because differential treatment options
for NSCLC subtypes were lacking, thoracic surgeons,
pulmonologists, and oncologists had simply classified lung
carcinomas into two categories: SCLC and NSCLC. Re-
cent clinical trials for NSCLC revealed that some chemo-
therapeutic regimens (e.g., pemetrexed) were apparently
more effective for non-SCC than for SCC,2 and the others
(e.g., bevacizumab) were of limited indication for SCC
because of fatal pulmonary hemorrhage.3 Consequently,
accurate histologic typing of NSCLC is essential.
A majority of lung cancers can be classified by light
microscopic examination alone into one of the four major
histologic types mentioned earlier. Nevertheless, up to two
thirds of patients with malignant neoplasms of the lung are
found inoperable, and the pathologic diagnosis for these
patients should be establishing using small samples such as
cytologic and/or biopsy specimens. Histologic typing is in
general challenging in poorly differentiated tumors. The
value of immunohistochemical panel to make histological
typing of NSCLC has been reported.4–9 For example,
thyroid transcription factor-1 (TTF-1) was sensitive and
specific for pulmonary AC, and p63 and cytokeratin 5/6
(CK5/6) were sensitive and specific for SCC.6,7,9 –11 Nev-
ertheless, recent reports indicated that these proteins are
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not very reliable, because a subset of SCC was positive for
TTF-1,5,7–9,12–17 and AC was positive for p635,8,9,18–21 or
CK5/6.5,8,11,14,22–24
Recently, several novel SCC markers have been intro-
duced into the literature. Desmocollin-3 is a protein found in
desmosomes, and its expression was detected in 100% of pul-
monary SCC.15 Glypican-3 is one of the extracellular, mem-
brane-bound, heparin sulfate proteoglycans, which is expressed
during fetal life and down-regulated after birth. Glypican-3
expression was detected in 55% of pulmonary SCC.25 S100
proteins belong to the calcium-binding proteins of the EF-hand
type and are involved in a variety of biological processes.
Although S100A2 is considered a tumor suppressor, its overex-
pression was reported in many carcinomas, including NSCLC.
S100A2 protein expression was detected in 84.2% of pulmonary
SCC.26 The exact mechanisms of action of S100A7 is unclear,
but its overexpression is associated with carcinogenesis.
S100A7 protein expression was detected in 36.0 to 53.2%
of pulmonary SCC.5,27 Sox2 is a transcription factor that
regulates airway epithelial differentiation, and the occur-
rence of its expression was reported to be 91% in pulmo-
nary SCC.28 Although the aforementioned markers showed
high sensitivity for pulmonary SCC, a comparison among
them has not been performed in the same cohort.
In this study, we investigated nine (four conventional
and five novel) SCC markers and AC-specific marker of
TTF-1 in pulmonary SCC and AC. We also analyzed the
correlation between expression and tumor grade and using
receiver operating characteristic (ROC) curve analysis.
PATIENTS AND METHODS
Case Selection
Institutional review board approved this study. The spec-
imens used in this study were from 318 patients who underwent
surgical resection for SCC, AC, or LCC at the National Cancer
Center Hospital (Tokyo, Japan) between 1997 and 2007. Histo-
logical diagnosis was based on the latest edition of the World
Health Organization classification.1 SCC and AC were subdi-
vided into three differentiation grades (Figures 1A–F).
Our final cohort was a total of 309 cases, including 150
patients with SCC (53 well-, 51 moderately, and 46 poorly
differentiated tumors) and 159 patients with AC (49 well-, 52
moderately, and 58 poorly differentiated tumors).
Microarray Construction
The most representative tumor areas were carefully
selected and marked on the hematoxylin and eosin-stained
slide. The tissue microarrays were assembled with a tissue-
arraying instrument (Azumaya, Tokyo, Japan). Considering
tumor heterogeneity, we used 2.0-mm diameter samples, and
FIGURE 1. Representative image of well-differentiated, moderately differentiated, and poorly differentiated squamous cell
carcinoma and adenocarcinoma (magnification, 10) (A). A well-differentiated squamous cell carcinoma shows an obvious
stratified pattern and significant keratinization (B). A moderately differentiated squamous cell carcinoma has a stratified pat-
tern; however, the degree of stratification and keratinization is lower than that of the well-differentiated type (C). A poorly dif-
ferentiated squamous cell carcinoma primarily exhibits solid growth and has focal stratified patterns and keratinization (D). A
well-differentiated adenocarcinoma is composed primarily of glands lined with a single layer of tumor cells (E). A moderately
differentiated adenocarcinoma is composed of glands with a cribriform growth pattern or fused with each other (F). A poorly
differentiated adenocarcinoma primarily exhibits solid growth patterns.
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the study specimens were routinely sampled with two repli-
cate cores of tumor from different areas.
Immunohistochemistry
For immunohistochemical staining, we routinely deparaf-
finized 4-m-thick sections from the tissue microarray block.
The sections were exposed to 3% hydrogen peroxide for 15
minutes to block endogenous peroxidase activity and then
washed in deionized water for 2 to 3 minutes. Detailed antigen
retrieval methods and antibody dilution for each primary anti-
body are listed (Table 1). We used an automated stainer (Dako,
Carpinteria, CA) for primary antibody incubation, following the
vendor’s protocol. ChemMate EnVisionTM (DAKO) detection
methods were used.
Positive staining was defined as cytoplasmic staining for
high-molecular-weight CK of 34E12 (HMCK) and CK5/6,
cytoplasmic and/or nuclear staining for S100A2 and S100A7,
nuclear staining for p63, Sox2, and TTF-1, distinct circumfer-
ential membrane staining for thrombomodulin and desmocol-
lin-3, and membranous and/or cytoplasmic staining for glypi-
can-3. We defined immunopositive cases as those with a mean
positive area 10% in two core samples. To analyze the extent
of immunoreactivity, we defined immunopositive cases as those
with a mean positive area of 50% in two core samples.
Statistical Analysis
Statistical analysis was performed using SPSS 12.0 for
Windows (SPSS, Chicago, IL). The area under the curve
(AUC) in ROC analysis was used to compare the ability of an
antibody to discriminate between SCC and AC. The Kruskal-
Wallis H test was used to compare categorical variables
between groups. The Dunnett multiple comparison test was
used to identify statistically significant differences between
categorical data. For analyzing the immunohistochemical
panels to differentiate between AC and SCC, we performed
multivariate analysis using logistic regression analysis. For a
comparison among models, the crossvalidated ROC-AUC
was used as a measure of performance of a predictive. In
addition, classification and regression tree analysis were also
performed. We based the pruning and selection of a tree on
10-fold crossvalidation.
RESULTS
Conventional SCC Marker Expression
Among conventional SCC markers (Figures 2A, B), the
most sensitive marker for SCC was p63 (148/150, 98.7%;
Figure 3A), followed by HMCK (146/150, 97.3%), CK5/6
(140/150, 93.3% Figure 3B), and thrombomodulin (119/150,
79.3%). Irrespective of tumor differentiation, HMCK and p63
had high sensitivity. In contrast, the sensitivity of CK5/6
(100% to 87%) and thrombomodulin (88.7% to 58.7%) de-
creased as tumor differentiation decreased. Among them,
statistical differences between tumor differentiation and pos-
itivity were observed in CK5/6 (p  0.032; well versus
poorly differentiated) and thrombomodulin (p  0.001; well
versus poorly and moderately versus poorly differentiated)
but not in p63 (p  0.572) and HMCK (p  0.181). On
analyzing the extent of immunoreactivity, high positive rates
of diffuse staining (50% area positive) were observed in
HMCK (83.3%), CK5/6 (74.0%), and p63 (95.3%) (Figure
2A). On the other hand, the diffuse positive rate of thrombo-
modulin was not very high (40.7%). All these markers show
that the diffuse positive rates decrease with the decrease in
tumor differentiation.
For AC, HMCK showed the highest positive rate (104/
156, 66.7%; Figure 3C) followed by p63 (76/157, 48.4%;
Figure 3D), thrombomodulin (32/159, 20.1%), and CK5/6
(2/159, 1.3%). Similar to SCC, immunohistochemical posi-
tivity of HMCK and p63 was not affected by tumor differ-
entiation. In contrast, immunohistochemical positivity of
thrombomodulin had tendency to be increased (14.3% to
27.6%; p  0.192) as tumor differentiation decreased. Im-
munohistochemical positivity of CK5/6 was extremely low
regardless of tumor differentiation (0% in well-, 1.9% in
moderately, and 1.7% in poorly differentiated tumors).
On analyzing the extent of immunoreactivity, a rela-
tively high positive rate of diffuse staining (50% area
positive) was observed in HMCK (39.1%). On the other
hand, we observed extremely low positive rates of diffuse
staining in CK5/6 (2.0%) and thrombomodulin (3.8%). It is
noteworthy that the diffuse positive rate of p63 was not very
high (13.4%), but it was consistently positive irrespective of
tumor differentiation (Figure 2B).
TABLE 1. Summary of Antibodies
Antibody Clone Antigen Retrieval Dilution Source
High-molecular-weight cytokeratin 34E12 Citrate buffer 1:100 DAKO, Carpinteria, CA
Cytokeratin 5/6 D5/16B4 TRS9 (DAKO) 1:50 DAKO
P63 4A4 Citrate buffer 1:400 DAKO
Thrombomodulin 1009 TRS9 1:100 DAKO
Desmocollin-3 Dsc3-U114 Citrate buffer Diluted Progen, Heildelberg, Germany
Glypican-3 1G12 Citrate buffer 1:200 Cell Margue, Rocklin, CA
S100A2 SH-L1 — 1:200 Sigma, St Louis, Mo
S100A7 47C1068 Citrate buffer 1:200 IMGENEX, San Diego, CA
Sox-2 Polyclonal Citrate buffer 1:1000 Chemicon, Temecula, CA
Thyroid transcription factor-1 SPT24 Citrate buffer 1:100 Leica/Novacastra, Newcastle, UK
TRS, target retrieval solution.
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Novel SCC Marker Expression
Among novel SCC markers (Figures 4A, B), the most
sensitive marker for SCC was Sox2 (120/150, 80.0%; Figure
5A), followed by desmocollin-3 (109/150, 72.7%; Figure 5B),
S100A7 (106/150, 70.7%; Figure 5C), S100A2 (95/150,
63.3%; Figure 5D), and glypican-3 (70/150, 46.7%; Figure
5E). Although immunohistochemical positivity of all novel
SCC markers generally decreased as tumor differentiation
decreased, the most sensitive marker in poorly differentiated
SCC was Sox2 (33/46, 71.7%). Among them, statistical
differences between tumor differentiation and positivity were
observed in desmocollin-3 (p  0.001; well versus poorly
differentiated), S100A2 (p  0.001; well versus moderately,
well versus poorly, and moderately versus poorly differenti-
ated), and S100A7 (p  0.001; well versus poorly, and
moderately versus poorly differentiated) but not in glypican-3
(p  0.485) and Sox2 (p  0.196). The extent of immuno-
reactivity, high positive rate for diffuse staining (50%
area positive) was observed in Sox2 (59.3%) (Figure 4A),
whereas diffuse positive rate of desmocolin-3 (24.0%),
FIGURE 2. Conventional squa-
mous cell carcinoma marker expres-
sion in squamous cell carcinoma
and adenocarcinoma. A, Bar graphs
depicting the comparative percent-
ages of positive immunohistochemi-
cal staining results for squamous cell
carcinoma. A white line, indicating
a positive result, denoted a mean
positive area of 50% in two core
samples. B, Bar graphs depicting the
comparative percentages of positive
immunohistochemical staining re-
sults for adenocarcinoma. A white
line, indicating a positive result, de-
noted a mean positive area of
50% in two core samples. HMCK,
high-molecular-weight cytokeratin;
CK, cytokeratin; Thrombo, throm-
bomodulin.
Journal of Thoracic Oncology • Volume 6, Number 7, July 2011 Utility of Immunohistochemical Markers
Copyright © 2011 by the International Association for the Study of Lung Cancer 1193
glypican-3 (11.3%), S100A2 (18.0%), and S100A7 (7.3%)
was not so high. As regards the extent of immunoreactiv-
ity, a high positive rate of diffuse staining (50% area
positive) was observed in Sox2 (59.3%) (Figure 4A). On
the other hand, the diffuse positive rates of desmocollin-3
(24.0%), glypican-3 (11.3%), S100A2 (18.0%), and
S100A7 (7.3%) were not very high.
For AC, S100A2 showed the highest positive rate
(56/158, 35.4%), followed by S100A7 (21/159, 13.2%),
glypican-3 (12/158, 7.6%), Sox2 (7/157, 4.5%), and desmo-
collin-3 (0/157, 0%). Immunohistochemical positivity of
glypican-3 (14.3% to 5.2%; p  0.101) and S100A2 (51% to
19%; p  0.002) decreased as tumor differentiation de-
creased. In contrast, immunohistochemical positivity of
S100A7 increased (0% to 24.1%; p  0.001) as tumor
differentiation decreased. Immunohistochemical positivity of
Sox2 was extremely low (2.1% in well, 5.9% in moderately,
and 5.2% in poorly differentiated tumors), and desmocollin-3
was consistently negative regardless of the tumor differenti-
ation state.
Specificity for SCC Markers
In the present cohort comprising 150 SCC and 159
ACC, the most specific marker for SCC among nine SCC
markers was desmocollin-3 (100%), followed by CK5/6
(98%), Sox2 (95.5%), glypican-3 (92.4%), S100A7 (86.8%),
thrombomodulin (79.9%), S100A2 (64.6%), p63 (51.6%),
and HMCK (33.3%) (Table 2).
TTF-1 Expression
TTF-1 expression was observed in 139 of the 159
(87.4%) AC cases. Although immunohistochemical positivity
decreased as tumor differentiation decreased (well differen-
tiated: 98.0%, moderately differentiated: 94.2%, and poorly
differentiated: 72.4%; p  0.001). The statistical differences
between tumor differentiations and positivity were observed
in well- versus poorly and moderately versus poorly differ-
entiated ACs, On the other hand, TTF-1 expression was
observed in 3 of the 150 (2.0%) SCC cases (Figure 6). They
consisted of two moderately differentiated cases and one
poorly differentiated case. Among the TTF-1-positive SCCs,
two cases were positive for six SCC markers, and one case
was positive for two SCC markers. All three cases were
positive for p63.
Analysis of Immunopositive Area >50% Cases
In conventional SCC markers for SCC cases (Figures
2A, B and 4A, B), most of positive cases for HMCK, CK5/6,
and p63 showed immunopositive area 50%, whereas ap-
proximately a half of thrombomodulin-positive cases showed
immunopositive area 50%.
In conventional SCC markers for AC cases, approx-
imately a half of HMCK-positive cases showed immuno-
positive area 50%. Approximately 1/3 p63-positive cases
showed immunopositive area 50%, whereas there was no
CK5/6 immunopositive area 50% cases, and rarely im-
munopositive area 50% cases was observed in thrombo-
moduin. In novel SCC markers for SCC cases, only Sox2
revealed that approximately 2/3 immunopositive cases
showed immunopositive area 50%, irrespective of tumor
differentiation, whereas desmocollin-3 and S100A2 re-
vealed that approximately a half of immunopositive cases
in well-differentiated SCC showed immunopositive area
50%, but these immunopositive area 50% cases de-
creased as tumor differentiation was decreased. In addi-
tion, immunopositive area 50% cases were rarely ob-
served in glypican-3 and S100A7.
In novel SCC markers for AC cases, immunopositive area
50% cases were rarely observed in glypican-3, S100A7, and
Sox2. S100A2 revealed that approximately 2/3 immunopositive
cases in well-differentiated AC showed immunopositive area
50%, but these immunopositive area 50% cases decreased
as tumor differentiation was decreased.
Analysis of Poorly Differentiated SCC and AC
Because correct histological typing in poorly differen-
tiated carcinomas is challenging in daily practice, we ana-
lyzed the significance of sensitivity of nine SCC markers and
TTF-1 between the subcohort comprising 46 poorly differen-
tiated SCCs and 58 poorly differentiated ACs. Among nine
SCC markers, the most sensitive marker for poorly differen-
tiated SCC was HMCK (46/46, 100%), followed by p63
(45/46, 97.8%), CK5/6 (40/46, 87.0%), Sox2 (33/46, 71.7%),
thrombomodulin (27/46, 58.7%), desmocollin-3 (24/46,
52.2%), S100A2 (23/46, 50%), glypican-3 (21/46, 45.7%),
and S100A7 (21/46, 45.7%). TTF-1 was positive in 1/46
(2.2%) poorly differentiated SCC.
FIGURE 3. Conventional squamous cell carcinoma marker
expression patterns. A, p63 showed diffuse and strong nu-
clear positivity in poorly differentiated squamous cell carci-
noma (magnification, 20). B, Cytokeratin 5/6 showed dif-
fuse and strong cytoplasmic positivity in poorly differentiated
squamous cell carcinoma (magnification, 20). C, High-mo-
lecular-weight cytokeratin showed diffuse and strong cyto-
plasmic positivity in well-differentiated adenocarcinoma.
Lower left portion of bronchial basal cells were internal posi-
tive control (magnification, 20). D, p63 showed diffuse
and strong nuclear positivity in well-differentiated adenocar-
cinoma. Middle left portion of bronchial basal cells was in-
ternal positive control (magnification, 10).
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Among nine SCC markers, the most specific marker for
poorly differentiated SCC was desmocollin-3 (100%), fol-
lowed by CK5/6 (98.3%), glypican-3 (94.8%) and Sox2
(94.8%), S100A2 (81%), S100A7 (75.9%), thrombomodulin
(72.4%), p63 (48.3%), and HMCK (36.8%).
ROC Curve Analysis
The area under the ROC curve (or AUC) represents
an optimal summary statistic for comparing the sensitivity
and specificity of the nine markers. For the cohort of 318
tumors including all histological grades, CK5/6 (0.96) had
the greatest AUC, followed by Sox2 (0.878), desmocol-
lin-3 (0.863), thrombomodulin (0.796), S100A7 (0.787),
p63 (0.751), glypican-3 (0.695), HMCK (0.653), and
S100A2 (0.639) (Table 2). The AUC of TTF-1 for diag-
nosing AC was 0.887.
Analyzing the subcohort comprising 46 poorly differ-
entiated SCCs and 58 poorly differentiated ACs, CK5/6
(0.926) had the greatest AUC, followed by Sox2 (0.833),
desmocollin-3 (0.761), p63 (0.731), glypican-3 (0.702),
HMCK (0.684), thrombomodulin (0.656), S100A2 (0.655),
and S100A7 (0.608) (Table 2). The AUC of TTF-1 for
diagnosing AC was 0.851.
Recommended Panel for Differentiation
between SCC and AC
The 10-fold crossvalidated classification and regression
tree analysis revealed that the combination of CK5/6 and
TTF-1 was the best immunohistochemical marker panel for
the differentiation between SCC and AC.
DISCUSSION
In this study, we found that CK5/6 was the best marker
among nine SCC markers that could differentiate between
pulmonary SCC and AC, because CK5/6 had the highest
FIGURE 4. Novel squamous cell
carcinoma markers expression rate
in squamous cell carcinoma and ad-
enocarcinoma. A, Bar graphs depict-
ing the comparative percentages of
positive immunohistochemical stain-
ing results for squamous cell carci-
noma. A white line, indicating a
positive result, denoted a mean pos-
itive area of 50% in two core sam-
ples. B, Bar graphs depicting the
comparative percentages of positive
immunohistochemical staining re-
sults for adenocarcinoma. A white
line, indicating a positive result, de-
noted a mean positive area of
50% in two core samples.
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AUC irrespective of tumor differentiation. Thus, the combi-
nation of CK5/6 and TTF-1 is the most recommended com-
bination of immunohistochemical markers. In this study, we
will discuss nine SCC markers of AUC value for all histo-
logical grades.
Although the CK5/6 expression rate in pulmonary SCC
ranged from 47 to 100%, all but one study24 reported that
positivity was more than 60%.5,7–9,11,14,29 In contrast, the
immunoreactivity of CK5/6 has also been reported in 0 to
64% of pulmonary ACs.5,7–9,11,14,22,24,29 Approximately two
thirds of the published studies reported that CK5/6 positivity
in pulmonary AC was less than 20%. A biochemical study
revealed that pulmonary alveolar cells express CK polypep-
tides typical of simple epithelia (CK 7, 8, 18, and 19),
whereas the bronchial epithelium expresses basic CK s (CK5,
small amounts of CK6) and acidic polypeptides (CK15 and
CK17). In their malignant counterparts, CK5 was not de-
tected in pulmonary ACs.30 These results indicated that
CK5/6 is a highly sensitive and specific marker for diagnos-
ing pulmonary SCC.
FIGURE 5. Novel squamous cell carcinoma marker expression patterns. A, Sox2 showed diffuse and strong nuclear positivity
in poorly differentiated squamous cell carcinoma (magnification, 20). B, Desmocollin-3 showed diffuse and strong membra-
nous positivity in poorly differentiated squamous cell carcinoma (magnification, 20). C, Central area of tumor nest was
strong positive for S100A7 (magnification, 10). D, Central and middle area of tumor nest was strong positive for S100A2
(magnification, 10). E, Glypican-3 showed membranous and cytoplasmic positivity in moderately differentiated squamous
cell carcinoma (magnification, 20).
TABLE 2. Sensitivity and Specificity of Squamous Cell Carcinoma-Positive markers and Receiver Operating
Characteristic Analysis
Antibody
All Histological
Grade
Limited Only to Poorly
Differentiated Carcinomas
Sensitivity (%) Specificity (%) AUC Sensitivity (%) Specificity (%) AUC
HMCK 97.3 33.3 0.653 100 36.8 0.684
CK5/6 93.3 98.0 0.96 87.0 98.3 0.926
p63 98.7 51.6 0.751 97.8 48.3 0.731
Thrombomodulin 79.3 79.9 0.796 58.7 72.4 0.656
Desmocollin-3 72.7 100 0.863 52.2 100 0.761
Glypican-3 46.3 92.4 0.695 45.7 94.8 0.702
S100A2 63.3 64.6 0.639 50 81 0.655
S100A7 70.7 86.8 0.787 45.7 75.9 0.608
Sox2 80 95.5 0.878 71.7 94.8 0.833
AUC, area under the curve; HMCK, high-molecular-weight cytokeratin; CK, cytokeratin.
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Among the novel markers, Sox2 was a highly sensitive
(80%) and specific (95.5%) marker for SCC. Sox2 is a
transcription factor that is involved in the maintenance of
embryonic stem-cell pluripotency and in multiple develop-
mental processes, including lung branching morphogene-
sis. The SOX2 gene is an oncogene that undergoes ampli-
fication in lung and esophageal SCCs.31 Comparative
genomic hybridization studies have demonstrated high-
level amplifications of 3q26, where SOX2 is located, in
SCC but not AC.32 Nevertheless, immunohistochemical
analysis revealed that Sox2 expression was detected in 10
to 50% of pulmonary AC.28,33
Desmocollin-3 was also found to be highly sensitive
and specific marker for SCC. Of note, this study showed that
desmocollin-3 was not expressed in AC, irrespective of tumor
differentiation, and had the highest specificity among the
nine markers tested. Nevertheless, desmocollin-3 expres-
sion in pulmonary SCC was influenced by tumor differen-
tiation more than Sox2. Recent analysis of complementary
DNA expression arrays revealed that the desmocollin-3
gene was up-regulated in SCC compared with AC.34,35
Desmocollin-3 protein expression was detected in 69 to
100% of SCC but only in 0 to 10% of pulmonary
AC.15,34,35These results indicated that desmocollin-3 was
the most specific marker for SCC.
Thrombomodulin was immunohistologically positive
in 79.3% of SCC, but immunohistological positivity de-
creased as tumor differentiation decreased (p  0.001).
Although thrombomodulin positivity in pulmonary AC
ranged from 10 to 20%, including in this study, thrombo-
modulin is expressed in a variety of normal cells, espe-
cially endothelial cells, and malignant tumors, such as
malignant mesothelioma.36 In practical settings, thrombo-
modulin was not very useful, because reactivity with
capillary vessels and necrotic debris sometimes made it
difficult to recognize true positivities.
S100A7 showed high sensitivity in well-differentiated
SCC, but there was a marked decrement of sensitivity in
poorly differentiated SCC (p  0.001), and there was less
specificity compared with Sox2 and desmocollin-3. A previ-
ous report revealed that S100A7 was a sensitive and specific
marker for pulmonary SCC.27 Compared with this report, our
study observed a higher sensitivity (70.7%) for all histologic
grades.27 No positivity for AC was observed in well-differ-
entiated AC, but positivity increased (24.1%) as tumor dif-
ferentiation decreased. These results indicated that these
discrepancies might reflect differences in patient’s cohorts,
especially proportion of poorly differentiation cases. From a
practical standpoint, S100A7 was not very useful because
both sensitivity and specificity were decreased in poorly
differentiated carcinomas.
We found that p63 was a sensitive, but not very spe-
cific, marker for diagnosing SCC. In normal tissues, p63 was
reported to be immunohistochemically detectable in basal
cells of all squamous epithelia and in basal cells of bronchial,
urothelial, and prostate epithelium. Furthermore, expression
of p63 has been investigated in a variety of tumors and found
to be overexpressed in SCC of various primary sites such as
head/neck, esophagus, cervix uteri, and anal canal, including
expression in 80 to 100% of pulmonary SCC.5,8,11,18,19,37,38
Although immunoreactivity of p63 has also been reported in
10 to 42% of pulmonary ACs.5,8,9,18–21The considerable rea-
sons that p63 had the lowest specificity for diagnosing SCC
in this study compared with other reports included different
sources of antibodies, dilutions, method of antigen retrieval,
and scoring system. Among them, the lower threshold used in
our scoring system (10% positive cells) was the most
important reason. Most of the reported and present study of
immunoreactivity for p63 in SCC is nuclear, strong, and
diffuse.36 Although the percentage of p63-positive cells in
AC is usually lower than that seen in SCC.11 It is of note that
among the p63-positive SCCs, 27.7% cases showed diffuse
(50% area positive) immunoreactivity.
Similar to a previous report,25 incidence of glypican-3
expression was low (7.6%) in AC and high (46.7%) in SCC.
Recently, glypican-3 is recognized as a potential target for
immunotherapy because glypican-3 has been detected in the
placenta and fetal liver but not in other adult organs. A phase
I clinical trial of a glypican-3-derived, peptide vaccine for
advanced hepatocellular carcinoma is underway. Although
recent clinical success with some new drugs, such as pem-
etrexed and bevacizumab, has been reported for NSCLC,
patients with SCC have not received the benefits. Because of
the immunoreactivity of glypican-3 in SCC, glypican-3 may
be considered as a target for the immunotherapy.
Antibody 3412 recognizes a set of HMCKs (CKs 1,
5, 10, and 14) that are expressed mainly in complex and
stratified epithelia. In the lung, this set of markers identifies
the basal and parabasal cells of the normal bronchi, and in
tumors, expression is restricted mainly to SCCs, whereas ACs
are typically negative.22 Nevertheless, HMCK expression
was reported in 26 to 60% of pulmonary AC,5,7–9,21,39 and one
of the HMCK components of CK14 expression was reported
in 21% of pulmonary AC.22 The higher positive rate of
FIGURE 6. Thyroid transcription factor-1 expression in squa-
mous cell carcinoma. Thyroid transcription factor-1 showed
diffuse and strong nuclear positivity in moderately differenti-
ated squamous cell carcinoma (magnification, 10).
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HMCK in pulmonary AC may be caused by CK14 expres-
sion, instead of CK5/6 expression.
S100A2 showed a high sensitivity in well-differenti-
ated SCC but a marked decrement (p  0.001) in sensitivity
in poorly differentiated SCC. Compared with a previous
report about the sensitivity of S100A2 for SCC,26 this study
found a similar sensitivity (88.7%) in well-differentiated
SCC, which decreased (63.3%) when all differentiated SCC
tumors were included in the analysis. These results indicated
that these discrepancies might reflect differences in patient’s
cohorts, especially proportion of poorly differentiation cases.
From a practical standpoint, S100A2 was not useful for
differentiating poorly differentiated carcinomas.
We also found that TTF-1 was a highly sensitive but
not completely specific marker. The high specificity of TTF-1
for ACs has been reported by previous studies,10 although
few studies have suggested that some SCCs (3% to 21%) may
be TTF-1 positive.5,7–9,12–17 Recently, a highly sensitive clone
of SPT24 has been reported to be less specific than the
conventional clone of 8G7G3/3.8,16 Among our TTF-1-posi-
tive SCCs, 66.7% cases were positive for six SCC markers. In
addition, Perner et al.40 found that 9% of SCCs showed
TTF-1 gene amplification. These findings indicate that the
high sensitivity of SPT24 can detect small amounts of TTF-1
protein expression.
Only a few reports have been published about the five
novel antibodies. It will be necessary to study a larger number
of cases to determine the utility of these markers. In addition,
using only a single marker for diagnosing poorly differenti-
ated carcinoma may result in misdiagnoses. In this study, we
have demonstrated that the combination of CK5/6 and TTF-1
is the most recommended combination of immunohistochem-
ical markers.
In this study, we used cores of 2.0-mm diameter from
the resected specimens selected to be representative of those
specimens. The drawback of this approach is that actual small
biopsy materials are not used, and therefore, factors particular
to biopsy specimens that may influence immunohistochem-
istry (tissue selection, processing, and fixation) are not intrin-
sically accounted for.
In conclusion, among nine SCC markers, CK5/6 is the
best marker for differentiating between SCC and AC, irre-
spective of the histological grade of the tumor. Among novel
SCC markers, Sox2 and desmocollin-3 are promising mark-
ers, but they do not exhibit absolute sensitivity and specificity
for SCC; therefore, the combination of CK5/6 and TTF-1 is
the most recommended combination of immunohistochemi-
cal markers.
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